How to Get Jardiance in Montana: Prescriptions, Telehealth, and Pharmacy Options

What Is Jardiance and Why Does It Matter?

Empagliflozin is an oral sodium-glucose cotransporter-2 (SGLT2) inhibitor approved by the FDA for type 2 diabetes, heart failure, and chronic kidney disease (CKD). It works by blocking glucose reabsorption in the proximal tubule of the kidney, forcing excess glucose out through urine while also reducing sodium retention and lowering intraglomerular pressure. The clinical benefit goes well beyond blood-sugar control.

In EMPA-REG OUTCOME (N=7,020 adults with type 2 diabetes and established cardiovascular disease), empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% versus placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [1]. Cardiovascular death specifically fell by 38% [1]. These numbers changed how cardiologists and endocrinologists think about glucose-lowering drugs entirely.

The EMPEROR-Reduced trial (N=3,730) later showed that empagliflozin cut the composite of cardiovascular death or hospitalization for heart failure by 25% in patients with heart failure and reduced ejection fraction (ejection fraction <40%), regardless of diabetes status (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) [2]. EMPEROR-Preserved (N=5,988) extended these findings to heart failure with preserved ejection fraction, reducing the same composite endpoint by 21% (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [3].

For CKD, the EMPA-KIDNEY trial (N=6,609) reported a 28% relative risk reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [4]. The FDA approved empagliflozin for CKD in 2023, referencing this trial directly [5].

The American Diabetes Association 2024 Standards of Care designate SGLT2 inhibitors as preferred add-on agents for patients with type 2 diabetes who also have atherosclerotic cardiovascular disease, heart failure, or CKD [6]. The 2022 AHA/ACC Heart Failure Guideline gives SGLT2 inhibitors a Class I recommendation for patients with heart failure with reduced ejection fraction [7].

Who Can Prescribe Jardiance in Montana?

Any licensed prescriber in Montana with full prescriptive authority can write a Jardiance prescription. That group includes MDs, DOs, nurse practitioners (NPs) with an active prescriptive authority endorsement, and physician assistants (PAs) operating under a collaborative agreement. Montana statute MCA 37-8-202 grants NPs independent prescriptive authority once they hold the appropriate certification, meaning no physician cosignature is required [8].

Telehealth prescribing is fully legal. Montana adopted explicit telehealth parity laws, and the Montana Board of Pharmacy and the Board of Medical Examiners both recognize electronically transmitted prescriptions from providers licensed in-state. A provider must establish a valid patient-provider relationship before prescribing. For most telehealth platforms, that means a synchronous video visit or, in some cases, a documented asynchronous intake with a clinical review. Phone-only encounters without video are generally not sufficient for a first prescription of a Schedule-exempt but clinically significant drug like empagliflozin.

The HealthRX clinical team follows a three-step verification process before issuing any empagliflozin prescription: confirmed diagnosis with supporting HbA1c or imaging documentation, baseline eGFR review, and a medication reconciliation check for drugs that raise hyperkalemia or hypotension risk (particularly ACE inhibitors, ARBs, and diuretics).

What Labs Are Required Before Starting Jardiance?

Before prescribing empagliflozin, a clinician must review renal function. The FDA label for Jardiance specifies that the drug is not recommended when eGFR falls below 20 mL/min/1.73 m2 for the diabetes and heart failure indications, and dosing considerations differ for the CKD indication [5]. Practically, every prescriber should obtain the following before writing the first prescription:

• Serum creatinine and eGFR (CKD-EPI 2021 equation preferred)
• Urinalysis or urine albumin-to-creatinine ratio (UACR) if CKD is a concern
• HbA1c if the indication is type 2 diabetes
• Basic metabolic panel to assess potassium, especially in patients already on renin-angiotensin-aldosterone system (RAAS) blockers
• Blood pressure reading, because empagliflozin produces modest systolic BP reductions of 3 to 5 mmHg, which can compound existing hypotension [9]

Most commercial labs in Montana (Quest, LabCorp, and local hospital outpatient labs) can process these panels within 24 to 48 hours. Telehealth platforms that operate in Montana typically provide lab requisition through one of these networks, so patients do not need a separate in-person visit just to draw blood.

A hemoglobin A1c of 7.0% or above generally satisfies the clinical threshold for initiating empagliflozin in type 2 diabetes. For heart failure or CKD indications, HbA1c is informative but not the prescribing criterion. The EMPEROR-Reduced trial enrolled patients with ejection fractions <40% regardless of glycemic status, and 47% of participants did not have diabetes [2].

How Does Telehealth Prescribing Work for Jardiance in Montana?

Montana is a large, rural state. For many residents, the nearest endocrinologist or cardiologist may be 90 to 200 miles away. Telehealth solves that access gap directly.

Here is the typical flow when using a telehealth service licensed in Montana:

1. Complete an online intake form covering medical history, current medications, and indication (diabetes, heart failure, or CKD).
2. Submit recent lab results or receive a lab requisition to complete before your visit.
3. Attend a synchronous video visit (15 to 25 minutes for most platforms). The clinician confirms the diagnosis, reviews labs, discusses side effects including genital mycotic infections (occurring in roughly 6% to 8% of patients) [9], urinary tract infections, and the rare risk of diabetic ketoacidosis (DKA) particularly in patients who are volume-depleted or fasting.
4. If appropriate, the clinician sends an electronic prescription to a pharmacy of your choice in Montana or to a mail-order pharmacy licensed to ship to Montana addresses.
5. A follow-up visit at 8 to 12 weeks reviews HbA1c response, weight, blood pressure, and any side effects.

Turnaround from intake form to prescription transmission is typically one to three business days. If lab results are already on hand, same-day prescribing after the video visit is possible.

The HealthRX Montana Access Framework identifies three patient profiles for whom telehealth empagliflozin initiation is most appropriate: (1) patients with established type 2 diabetes on metformin who have an eGFR above 45 mL/min/1.73 m2 and recent HbA1c documentation; (2) patients with a prior cardiology diagnosis of heart failure who are stable on guideline-directed medical therapy and want to add an SGLT2 inhibitor per their cardiologist's recommendation but lack timely local follow-up; (3) patients with CKD stage 3a or 3b (eGFR 30 to 59 mL/min/1.73 m2) and UACR above 200 mg/g who have been identified through primary care screening but whose nephrologist referral wait time exceeds 60 days. All three profiles require lab documentation within the prior 90 days.

Montana Medicaid, Commercial Insurance, and Prior Authorization

Montana Medicaid does not cover Jardiance as of mid-2025. Patients on Medicaid must either pay out-of-pocket, pursue alternative SGLT2 inhibitors that may appear on the Medicaid preferred drug list, or appeal through the Medicaid prior authorization (PA) process for medical necessity.

For commercial insurance, prior authorization is common. Most Montana plans that follow the state's insurance regulations require at least one of the following before approving Jardiance:

• Documentation of type 2 diabetes with HbA1c above a plan-specified threshold (commonly 7.5% or 8.0%)
• Evidence of a cardiovascular event, heart failure diagnosis, or CKD stage, depending on indication
• Failure of or contraindication to metformin for the diabetes indication (some plans require a 90-day trial)
• A letter of medical necessity from the prescribing provider, citing the relevant guideline (the ADA 2024 Standards or the AHA/ACC 2022 Heart Failure Guideline)

The Boehringer Ingelheim and Lilly Jardiance Savings Card can reduce out-of-pocket costs to as low as $10 per month for commercially insured patients who meet eligibility criteria. Uninsured patients may qualify for the Lilly Cares Foundation patient assistance program, which provides Jardiance at no cost to patients below 400% of the federal poverty level.

A well-documented PA request shortens approval time considerably. The ADA's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a sodium-glucose cotransporter 2 inhibitor with demonstrated cardiovascular benefit is recommended as part of the glucose-lowering regimen" [6]. Quoting this language directly in a PA letter, alongside the patient's most recent eGFR and cardiovascular history, gives insurance reviewers the clinical and guideline basis to approve on first submission.

Can You Transfer a Jardiance Prescription to Montana?

Yes. Federal and Montana state law both permit the transfer of a non-controlled prescription between licensed pharmacies across state lines, with some restrictions. The receiving Montana pharmacy must be licensed by the Montana Board of Pharmacy, and the transferring pharmacy can generally transfer a prescription only once (for prescriptions with remaining refills). Chain pharmacies with locations in Montana (Walgreens, CVS, Walmart Pharmacy, and Albertsons) can support electronic transfers from out-of-state locations in minutes.

Patients relocating to Montana who need to continue Jardiance without interruption should ask the out-of-state prescriber for a written or electronically transmitted prescription that can be taken to a Montana pharmacy directly. If the prescriber is no longer reachable, a telehealth provider licensed in Montana can review records and issue a new prescription, typically within 48 hours.

Are 503A Pharmacies in Montana Licensed to Dispense Empagliflozin?

503A pharmacies in Montana are state-licensed compounding pharmacies that operate under USP Chapter 795 and 797 standards and are regulated by the Montana Board of Pharmacy [10]. They are legally permitted to dispense empagliflozin. However, compounded empagliflozin is not FDA-approved, and the FDA has not designated empagliflozin as a drug in shortage (unlike semaglutide), so there is no pathway for 503B outsourcing facilities to compound it at scale [5].

For most patients, the branded Jardiance tablet (10 mg or 25 mg) from a retail or mail-order pharmacy is the appropriate and most cost-effective option when savings card programs are applied. Compounding may be considered in rare cases where a patient has a documented allergy to a tablet excipient and needs an alternative delivery form, but this requires a prescriber-documented medical need and explicit pharmacy consultation.

How Long Until You Receive Jardiance in Montana?

The total timeline from first telehealth contact to having the medication in hand breaks down roughly as follows:

• Intake form and lab review: 1 to 2 days (or same day if labs are already available)
• Synchronous video visit: scheduled within 1 to 3 days on most platforms
• Prescription transmission to pharmacy: same day as visit
• Local retail pharmacy fill: 2 to 24 hours after transmission
• Mail-order pharmacy delivery within Montana: 3 to 5 business days (standard shipping), 1 to 2 business days (expedited)

Patients in rural Montana zip codes served by mail-order services like Express Scripts, CVS Caremark, or OptumRx typically see delivery within five business days. Some platforms that partner with specific mail-order pharmacies offer expedited processing, reducing that window to two or three days.

The one variable that extends timelines is prior authorization. If a commercial insurer requires PA and the prescriber submits documentation on the same day as the visit, most Montana plans respond within three to five business days. Urgent or expedited PA requests (for acute clinical situations) must receive a response within 72 hours under federal guidelines applicable to most commercial plans.

Dosing, Titration, and Monitoring After Starting Jardiance

Jardiance comes in two tablet strengths: 10 mg and 25 mg, both taken once daily in the morning, with or without food [5]. The standard starting dose for type 2 diabetes is 10 mg once daily. The 25 mg dose is available for additional glycemic lowering in patients who tolerate the 10 mg dose and have eGFR of 45 mL/min/1.73 m2 or above.

For heart failure and CKD indications, the approved dose is 10 mg once daily regardless of eGFR, down to the minimum thresholds specified in the label [5].

Monitoring after initiation should include:

• Repeat eGFR and serum creatinine at 4 to 6 weeks (a transient 5% to 10% dip in eGFR is expected and not a reason to discontinue) [4]
• HbA1c at 3 months for the diabetes indication
• Blood pressure at each follow-up visit
• Assessment for genital mycotic infections, particularly in women and uncircumcised men
• Counseling to hold empagliflozin 3 to 4 days before any elective surgery or prolonged fasting period to reduce DKA risk [5]

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity and Type 2 Diabetes notes that SGLT2 inhibitors produce mean body weight reductions of 2 to 3 kg at 26 weeks in the diabetes population, an effect attributed primarily to glycosuria and modest osmotic diuresis rather than appetite suppression [11]. This is modest compared to GLP-1 receptor agonists but represents a clinically meaningful benefit for patients with BMI above 30 kg/m2.

Side Effects and Safety Considerations Specific to Montana Patients

Montana's climate and geography introduce a few practical safety considerations that a prescribing provider should discuss:

• Dehydration risk is elevated during summer wildfire season or high-altitude outdoor activity. Empagliflozin's osmotic diuresis effect can worsen volume depletion. Patients should increase fluid intake and temporarily hold the medication if they develop diarrhea, vomiting, or are unable to eat and drink normally for more than 12 hours [5].
• Cold-weather skin care matters because genital mycotic infections, the most common side effect occurring in 6% to 8% of treated patients [9], may be underreported in populations less accustomed to discussing this with providers. Telehealth follow-up visits at 8 weeks create a structured opportunity to screen for this.
• Drug interactions with common Montana patient profiles deserve attention. Patients on loop diuretics for heart failure may experience additive diuresis. Those on lithium (used for bipolar disorder, which has elevated prevalence in rural Montana populations) require monitoring, as SGLT2 inhibitors may modestly increase lithium levels by altering renal sodium handling [12].

The FDA label carries a boxed warning for lower limb amputation risk with canagliflozin (another SGLT2 inhibitor) but does not carry the same black box warning for empagliflozin. Post-marketing surveillance data through 2024 have not identified a significant amputation signal with empagliflozin at the same magnitude seen with canagliflozin [5].

Getting Started with HealthRX in Montana

Montana residents can request a Jardiance evaluation through the HealthRX platform by completing the online intake, uploading recent labs (or requesting a requisition for a local draw), and scheduling a video visit with a HealthRX clinician licensed in Montana. The HealthRX medical team operates under protocols aligned with the ADA 2024 Standards of Care [6] and the AHA/ACC 2022 Heart Failure Guideline [7]. Prescriptions are transmitted electronically to the pharmacy of the patient's choice, including mail-order services that ship to all Montana zip codes.

Patients with an eGFR above 30 mL/min/1.73 m2 and a documented diagnosis of type 2 diabetes, heart failure, or CKD are eligible for evaluation. Those with eGFR between 20 and 29 mL/min/1.73 m2 may still qualify under the CKD indication pending individual clinical review. Anyone with eGFR <20 mL/min/1.73 m2 is not a candidate for empagliflozin under current FDA labeling [5].